We are live on ! Find out more
SABS icon

SAB Biotherapeutics
SABS

38 hedge funds and large institutions have $2.42M invested in SAB Biotherapeutics in 2022 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 9 increasing their positions, 9 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

4% more capital invested

Capital invested by funds: $2.32M → $2.42M (+$96.9K)

0.18% more ownership

Funds ownership: 0.77% → 0.95% (+0.18%)

0% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 8

0% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 9

5% less funds holding

Funds holding: 40 → 38 (-2)

Holders
38
Holders Change
-2
Holders Change %
-5%
% of All Funds
0.61%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
9
Reduced
9
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
V
Veritable
Delaware
+$423K
2
WAM
Warberg Asset Management
Illinois
+$339K
3
HighTower Advisors
HighTower Advisors
Illinois
+$69.4K
4
Citadel Advisors
Citadel Advisors
Florida
+$63.1K
5
SOS
Silver Oak Securities
Tennessee
+$47.5K

Top Sellers

Rank Fund Capital Flow
1
MC
Meteora Capital
Florida
-$105K
2
SCM
Shaolin Capital Management
Florida
-$35.1K
3
Millennium Management
Millennium Management
New York
-$27K
4
Jane Street
Jane Street
New York
-$17K
5
BlackRock
BlackRock
New York
-$16.1K
Name Holding Trade Value Shares
Change 		Change in
Stake
TRCT
26
Tower Research Capital (TRC)
New York
$7K -$2.04K -223 -16%
Susquehanna International Group
27
Susquehanna International Group
Pennsylvania
$6.75K +$10.5K +1,144 New
KAS
28
Kestra Advisory Services
Texas
$6.49K – – –
Baird Financial Group
29
Baird Financial Group
Wisconsin
$6K +$9.14K +1,000 New
1SB
30
1ST Source Bank
Indiana
$5.9K – – –
UBS Group
31
UBS Group
Switzerland
$4.09K +$4.96K +543 +362%
Royal Bank of Canada
32
Royal Bank of Canada
Ontario, Canada
$3K -$274 -30 -6%
JP Morgan Chase
33
JP Morgan Chase
New York
$1K -$1.6K -175 -67%
MCC
34
Money Concepts Capital
Florida
$147 +$228 +25 New
Wells Fargo
35
Wells Fargo
California
$109 +$9 +1 +6%
Bank of America
36
Bank of America
North Carolina
$22 -$393 -43 -91%
Millennium Management
37
Millennium Management
New York
– -$27K -3,855 Closed
Jane Street
38
Jane Street
New York
– -$17K -2,395 Closed
Goldman Sachs
39
Goldman Sachs
New York
– -$9K -1,262 Closed
Fidelity Investments
40
Fidelity Investments
Massachusetts
– -$6K -900 Closed
WAM
41
Wolverine Asset Management
Illinois
– -$2K -393 Closed
NA
42
NewEdge Advisors
Louisiana
– +$137 +15 New
1
2

SABS Hedge Fund Activity: Q4 2022 in Review

38 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in SAB Biotherapeutics (SABS) for Q4 2022, worth a combined $2.42M — up 4.2% from $2.32M a quarter earlier.

Fund positioning in SABS was balanced in Q4 2022: 8 funds opened new positions, 8 closed out, 9 added to existing stakes and 9 trimmed.

The largest buyer was Veritable, adding an estimated $423K. The largest seller was Meteora Capital, cutting an estimated $105K.

  • 38 institutional investors held SAB Biotherapeutics (SABS) as of Q4 2022, down from 40 in Q3 2022.
  • Funds reported $2.42M of SAB Biotherapeutics stock for Q4 2022, up 4.2% quarter-over-quarter.
  • 8 funds opened new SAB Biotherapeutics positions in Q4 2022 and 8 closed out, a net change of 0 holders.
  • The largest SAB Biotherapeutics buyer in Q4 2022 was Veritable, an estimated $423K added.
  • The largest SAB Biotherapeutics seller in Q4 2022 was Meteora Capital, an estimated $105K sold.

Based on aggregated 13F filings for Q4 2022.